These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36086817)

  • 1. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
    Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
    Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
    Wei W; Ma H; Yang D; Sun B; Tang J; Zhu Y; Chen X; Huang X; Liu J; Hu Z; Liu T; Zou L; Zhao X
    Blood Adv; 2023 Jul; 7(13):2941-2951. PubMed ID: 36848638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
    Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
    Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
    Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
    Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
    Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
    Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
    Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
    Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
    Zhang Y; Li C; Du M; Jiang H; Luo W; Tang L; Kang Y; Xu J; Wu Z; Wang X; Huang Z; Zhang Y; Wu D; Chang AH; Hu Y; Mei H
    Blood Cancer J; 2023 Apr; 13(1):61. PubMed ID: 37095094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
    Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
    Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
    Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.